ライフサイエンスコーパス: reverse transcriptase

1 merase chain reaction using human telomerase reverse transcriptase.

2 nd is aided in elongation by murine leukemia reverse transcriptase.

3 g a novel diversity-generating system with a reverse transcriptase.

4 targets the RNA template of human telomerase reverse transcriptase.

5 rations and temperatures and apply it to HIV reverse transcriptase.

6 matches using a thermostable group II intron reverse transcriptase.

7 ptide sequence derived from human telomerase reverse transcriptase.

8 d by human DNA polymerases relative to viral reverse transcriptases.

9 nhibited mRNA expression of human telomerase reverse transcriptase, a catalytic subunit of telomerase

10 sights into the regulatory interplay between reverse transcriptase, A3G and cellular DNA repair machi

11 osphorylated Tbk1 and, importantly, blocking reverse transcriptase activity suppressed the expression

12 found to also be capable of functioning as a reverse transcriptase, an activity that has never been d

13 Quantitative reverse transcriptase analysis demonstrated a 2-fold inc

14 of hepatitis B virus (HBV) quasispecies with reverse transcriptase and HBV surface antigen (HBsAg) he

15 of the branch site emerges between the Prp8 reverse transcriptase and linker domains and extends tow

16 of induced fit in enzyme specificity of HIV reverse transcriptase and many other enzymes.

17 A and RNA targets using polymerase with both reverse-transcriptase and strand displacement activities

18 IV RNA (1.3-kb fragment of p6, protease, and reverse transcriptase) and the levels of HIV RNA in sing

19 unodeficiency virus type 1 (HIV-1) protease, reverse transcriptase, and integrase sequences-three gen

20 RNA dependent DNA-polymerases, reverse transcriptases, are key enzymes for retroviruses

21 We found that (th)A is recognized by AMV reverse transcriptase as A, and is deaminated rapidly by

22 rid decreases the rate of both human and HIV reverse transcriptase-associated RNase H-mediated cleava

23 osomal frameshifting, is shown here to limit reverse transcriptase base substitution and indel 'error

24 e developed a high-throughput variant of the reverse-transcriptase-based method for identifying 2'-O-

25 n TR RNA and is dependent on the DGR-encoded reverse transcriptase (bRT) and accessory variability de

26 inery, and identify the suppression of HIV-1 reverse transcriptase by a directly interacting host pro

27 tures and G-rich sequences, ahead of diverse reverse transcriptases can be strong stimulators for sli

28 ingers domain" (IFD) in the human telomerase reverse transcriptase catalytic subunit (hTERT) have pre

29 elomere disorder." RMRP binds the telomerase reverse transcriptase (catalytic subunit) in some cell l

30 Reverse transcriptase-catalyzed reverse transcription cr

31 there were no fixed mutations in the Gag or reverse transcriptase coding sequence.

32 rosis by activation of fibroblast telomerase reverse transcriptase-dependent proliferation, motility,

33 The results revealed three interconverting reverse transcriptase-DNA/RNA species; 43% were active f

34 Mutation V111I in the HIV-2 reverse transcriptase enzyme was identified in patients

35 ications in the RNA were not detected by the reverse transcriptase enzyme.

36 ey contributor to HIV-1 genetic variation is reverse transcriptase errors.

37 ecific ligation probes than methods that use reverse transcriptase for cDNA synthesis of miRNA.

38 The organization of the t/PK on telomerase reverse transcriptase for medaka and human is modeled ba

39 N-terminal fusion proteins of the telomerase reverse transcriptase from its endogenous locus.

40 and IN, as well as the spatial separation of reverse transcriptase from the viral genome during early

41 dependent expression of the human telomerase reverse transcriptase gene (hTERT).

42 s here show that at the same shift motif HIV reverse transcriptase generates -1 and +1 indels with th

43 Here, we demonstrate that human telomerase reverse transcriptase (hTERT) activates vascular epithel

44 icted peptides derived from human telomerase reverse transcriptase (hTERT) and referred as universal

45 The human telomerase reverse transcriptase (hTERT) gene is repressed in most

46 riptional activation of the human telomerase reverse transcriptase (hTERT) gene, which remains repres

47 exes in the promoter of the human telomerase reverse transcriptase (hTERT) gene.

48 Human telomerase reverse transcriptase (hTERT) is overexpressed in cancer

49 Human telomerase reverse transcriptase (hTERT) plays a key role in tumor

50 ytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), is overexpressed in appro

51 he independent and simultaneous discovery of reverse transcriptase in retroviruses (then RNA tumor vi

52 ch ultimately was proven by his discovery of reverse transcriptase in Rous sarcoma virus virions.

53 rus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and l

54 d through POT1/TRF2 and via human telomerase reverse transcriptase inhibition through JNK activation.

55 "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site.

56 led RT in the presence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV)

57 mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%)

58 y abacavir+lamivudine) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 3 NRTIs as lo

59 eficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutat

60 e risk factors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.

61 ttributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance.

62 n protease inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens w

63 dine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or ef

64 il fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone.

65 MS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maint

66 t frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%),

67 individuals; 15.8% had nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, 9.8%

68 Treatment with the reverse transcriptase inhibitor 3TC resulted in decrease

69 a boosted darunavir regimen with nucleoside reverse transcriptase inhibitor background treatment for

70 localization of LysRS, but treatment with a reverse transcriptase inhibitor does not, suggesting tha

71 No individual ARV in the reverse transcriptase inhibitor drug classes was associa

72 tance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identifie

73 Here we analyzed whether abacavir, an HIV-1 reverse transcriptase inhibitor often inducing severe de

74 of a first-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRTIs.

75 enofovir alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cell

76 erapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

77 ularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior to combina

78 imilar proportions of overall and nucleoside reverse transcriptase inhibitor-associated minority vari

79 ipant in the atazanavir group had nucleoside reverse transcriptase inhibitor-associated resistance th

80 nce interval [CI], 90%-99.7%); nonnucleoside reverse transcriptase inhibitor-based, 100% (95% CI, 91%

81 ed patients failing an initial nonnucleoside reverse-transcriptase inhibitor (NNRTI) regimen in Afric

82 over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in pe

83 or (NRTI) resistance, 9.8% had nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, and

84 llows: exposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ra

85 icipants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations wer

86 ontaining dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between

87 eekly CD4 counts and to receive 2 nucleoside reverse transcriptase inhibitors (2NRTI, mainly abacavir

88 on for NNRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and protease inh

89 ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boos

90 New non-nucleoside reverse transcriptase inhibitors (NNRTI), which are simi

91 aluated the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etra

92 riptase inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 2 protease

93 iral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromi

94 e prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (9

95 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) that target th

96 ation of a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) with a novel a

97 mainly driven by resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).

98 ministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended

99 Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essenti

100 regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integra

101 Nucleoside reverse transcriptase inhibitors (NRTIs) with L-stereoch

102 ease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs).

103 eened the efficacy of commercially available reverse transcriptase inhibitors (RTIs) at inhibiting th

104 ested to be a major substrate for TREX1, and reverse transcriptase inhibitors (RTIs) were proposed as

105 the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candi

106 in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integrase inhibitor

107 core </=2 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunav

108 eiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpiviri

109 We further show that the addition of reverse transcriptase inhibitors effectively suppresses

110 sted proteasome inhibitors and nonnucleotide reverse transcriptase inhibitors in the cART regimen, in

111 her effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inh

112 d first-line regimens based on nonnucleoside reverse transcriptase inhibitors or integrase inhibitors

113 ase inhibitors, nonnucleoside and nucleotide reverse transcriptase inhibitors TDR mutations, namely,

114 bserved with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying abacavir a

115 pregnancy, 1 of which was without nucleoside reverse transcriptase inhibitors, infants had a specific

116 as 2-LTR quantification and the addition of reverse transcriptase inhibitors, is crucial to fully el

117 resistance to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, respectively.

118 l antiretroviral therapy with two nucleoside reverse transcriptase inhibitors.

119 rs (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

120 o paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line a

121 is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line

122 ndard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line com

123 o 12 HIV-1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 non-nucleosi

124 In this model, reverse-transcriptase inhibitors rescued the neurotoxici

125 The template for telomerase reverse transcriptase is within the RNA subunit of the r

126 equires the specific interaction of A3G with reverse transcriptase itself.

127 Subsequent studies of reverse transcriptase led to the elucidation of the mech

128 This assay is based on reverse transcriptase loop-mediated isothermal amplifica

129 s that large A3G oligomers could block HIV-1 reverse transcriptase-mediated DNA synthesis, thereby in

130 forming catalytic-inactive dimers that block reverse transcriptase-mediated DNA synthesis.

131 ce relies on telomeric repeat synthesis by a reverse transcriptase named telomerase.

132 rotease (both groups), eight (13%) of 64 for reverse transcriptase (NtRTI group) and 16 (20%) of 79 f

133 rupt the binding between the protein subunit reverse transcriptase of the telomerase and its nucleic

134 atitis B virus (HBV) encodes a multifunction reverse transcriptase or polymerase (P), which is compos

135 around the pregenomic RNA (pgRNA) and viral reverse transcriptase (P).

136 nds (5' RACE) for HIV-1 RNA and quantitative reverse transcriptase PCR (qRT-PCR).

137 genotype, and the vaccine-specific real-time reverse transcriptase PCR (rRT-PCR) assay described by F

138 developed and validated a one-step multiplex reverse transcriptase PCR (RT-PCR) to simultaneously det

139 The assays were evaluated with reverse transcriptase PCR (RT-PCR) using 411 nasopharyng

140 One-step reverse transcriptase PCR (RT-PCR) was performed in pico

141 ital PCR (ddPCR), and real-time quantitative reverse transcriptase PCR (RT-qPCR) from nine human cell

142 Results from quantitative reverse transcriptase PCR analysis clearly demonstrated

143 creened for the presence of SVA by real-time reverse transcriptase PCR and virus isolation.

144 Reverse transcriptase PCR demonstrated minor intron rete

145 On admission, reverse transcriptase PCR identified Ebola virus RNA at

146 A validation was carried out by quantitative reverse transcriptase PCR in 2 different set of samples.

147 This was confirmed by quantitative reverse transcriptase PCR in infected and uninfected gas

148 and 30 miRNAs was confirmed by quantitative reverse transcriptase PCR in samples from set 1 and set

149 Reverse transcriptase PCR showed that fruRBA formed an o

150 mRNA levels from tissues are measured using reverse transcriptase PCR, microarray analysis or high-t

151 RL), (ii) detection of T. pallidum in CSF by reverse transcriptase PCR, or (iii) new vision loss or h

152 Using reverse transcriptase PCR, we showed that ORF011 and ORF

153 from mice and analyzed histologically and by reverse transcriptase PCR; leukocytes were isolated, sti

154 d gene-expression changes using quantitative reverse-transcriptase PCR (qRT-PCR), immunofluorescence,

155 ined using immunofluorescence, western blot, reverse-transcriptase PCR, chromatin immunoprecipitation

156 logical methods, including culture, EIA, and reverse-transcriptase PCR.

157 expertise requirements limit the utility of reverse transcriptase-PCR methods for rapid diagnostics.

158 Using microarrays, reverse transcriptase-PCR, and immunohistochemistry, the

159 asive bladder cancer (NMIBC) by quantitative reverse transcriptase-PCR.

160 anscriptome analysis, quantitative real-time reverse-transcriptase-PCR, and quantitative immunohistoc

161 HIV reverse transcriptase plays a central role in viral repl

162 ts receptors was analyzed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR

163 IHC) for cytokeratin (AE1/AE3) and real-time reverse transcriptase polymerase chain reaction (RT-PCR)

164 istochemistry underwent molecular staging by reverse transcriptase polymerase chain reaction (RT-PCR)

165 vity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay co

166 mbedded breast cancer tumors, a quantitative reverse transcriptase polymerase chain reaction assay wa

167 sensitive genes was explored by quantitative reverse transcriptase polymerase chain reaction in rat p

168 Among the remaining patients, using reverse transcriptase polymerase chain reaction or trans

169 t is, providing results in <30 minutes) with reverse transcriptase polymerase chain reaction referenc

170 Quantitative reverse transcriptase polymerase chain reaction revealed

171 n, laser-assisted microdissection and nested reverse transcriptase polymerase chain reaction were per

172 ion levels of the receptor were evaluated by reverse transcriptase polymerase chain reaction, and inf

173 Measurements: The primary outcome was reverse transcriptase polymerase chain reaction-confirme

174 ndidate miRNAs were verified by quantitative reverse transcriptase polymerase chain reaction.

175 re selected for verification by quantitative reverse transcriptase polymerase chain reaction.

176 In training, using reverse-transcriptase polymerase chain reaction (PCR), w

177 level was assessed in tumors by quantitative reverse-transcriptase polymerase chain reaction and immu

178 Reverse-transcriptase polymerase chain reaction and immu

179 ssed and monitored in plasma using real-time reverse-transcriptase polymerase chain reaction assays.

180 ability that a virus detected with real-time reverse-transcriptase polymerase chain reaction in patie

181 was detected in cerebrospinal fluid (CSF) by reverse-transcriptase polymerase chain reaction of 16S r

182 , and gene profiling (quantitative real-time reverse-transcriptase polymerase chain reaction).

183 aine-treated mice were used for quantitative reverse-transcriptase polymerase chain reaction, immunoc

184 nrolled asymptomatic controls with real-time reverse-transcriptase polymerase chain reaction.

185 pressions were studied by flow cytometry and reverse-transcriptase polymerase chain reaction.

186 ompare the relative vaccine efficacy against reverse-transcriptase polymerase-chain-reaction (RT-PCR)

187 These results were validated by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)

188 ybridization showed PRKCA rearrangement, and reverse transcriptase-polymerase chain reaction confirme

189 Both PLP1 antibody staining and reverse transcriptase-polymerase chain reaction for plp1

190 Results were validated by using quantitative reverse transcriptase-polymerase chain reaction in 350 s

191 he available transcriptomic data followed by reverse transcriptase-polymerase chain reaction suggeste

192 et SFRP1 was also quantified by quantitative reverse transcriptase-polymerase chain reaction, and DNA

193 two experimental COPD models by quantitative reverse transcriptase-polymerase chain reaction, immunob

194 F versus control subjects using quantitative reverse transcriptase-polymerase chain reaction, immunoh

195 ng immunofluorescence, Western blotting, and reverse transcriptase-polymerase chain reaction, respect

196 By reverse transcriptase-polymerase chain reaction, we conf

197 Quantitative reverse transcriptase-polymerase chain reaction, Western

198 sured by histology, Western blot, ELISA, and reverse transcriptase-polymerase chain reaction.

199 l fluid were tested for ZIKV using real-time reverse-transcriptase-polymerase chain reaction and an I

200 eline were tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR)

201 ing 55 men) in whom ZIKV RNA was detected on reverse-transcriptase-polymerase-chain-reaction (RT-PCR)

202 We performed reverse-transcriptase-polymerase-chain-reaction (RT-PCR)

203 ZIKV was found in the fetal brain tissue on reverse-transcriptase-polymerase-chain-reaction (RT-PCR)

204 f which 2485 (4%) were confirmed by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR)

205 structural protein 1 antigen immunoassay and reverse-transcriptase-polymerase-chain-reaction assays.

206 tested blood and urine specimens for ZIKV by reverse-transcriptase-polymerase-chain-reaction assays.

207 ted cells and, through endogenous transposon reverse transcriptases, produce virus-derived complement

208 cture and function of the retroviral enzymes-reverse transcriptase, protease, and integrase-and have

209 HIV strains resistant to drugs targeting HIV reverse transcriptase, protease, integrase, and corecept

210 five representative sequence variants of the reverse transcriptase protein (RT) of hepatitis B virus

211 F. alocis were quantified and compared using reverse-transcriptase qPCR.

212 a-glucuronidase (GUS) activity, quantitative reverse transcriptase (qRT)-PCR, zymography, and chromat

213 was evaluated in all specimens collected by reverse transcriptase quantitative PCR (RT-qPCR) targeti

214 as assessed by faecal shedding of Sabin 2 by reverse transcriptase quantitative PCR (RT-qPCR).

215 ty assays and chromatin immunoprecipitation, reverse transcriptase quantitative PCR and western blott

216 atient-derived leukocytes were determined by reverse transcriptase quantitative polymerase chain reac

217 ere asthma using high-throughput, stem-loop, reverse transcriptase quantitative real-time PCR miRNA e

218 examined by using in situ hybridization and reverse transcriptase quantitative real-time PCR.

219 ndia, were compared using flow cytometry and reverse-transcriptase quantitative polymerase chain reac

220 NA profiling using high throughput stem-loop reverse-transcriptase quantitative polymerase chain reac

221 f miRNA-218-5p (miR-218-5p) was validated by reverse-transcriptase quantitative polymerase chain reac

222 We used a reverse-transcriptase quantitative polymerase-chain-reac

223 h inability to detect several viral mRNAs by reverse transcriptase-quantitative PCR, no production of

224 pe lectins were assessed in ileal tissues by reverse transcriptase-quantitative polymerase chain reac

225 specimens, and in healthy skin specimens by reverse transcriptase-quantitative polymerase chain reac

226 Single-cell multiplex reverse transcriptase-quantitative polymerase chain reac

227 particles are prematurely degraded, whereas reverse transcriptase remains active and stably associat

228 rematurely degraded in target cells, whereas reverse transcriptase remains active and stably associat

229 Telomerase is the essential reverse transcriptase required for linear chromosome mai

230 cal, and crystallographic studies with HIV-1 reverse transcriptase revealed that alpha-CNPs mimic the

231 The reverse transcriptase ribozyme can incorporate all four

232 ial steps are catalyzed by the HIV-1 enzymes reverse transcriptase (RT) and integrase (IN), respectiv

233 tegration are catalyzed by the viral enzymes reverse transcriptase (RT) and integrase (IN), respectiv

234 ng at the single molecule level, using HIV-1 reverse transcriptase (RT) as a model system.

235 Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RN

236 Targeting the clinically unvalidated reverse transcriptase (RT) associated ribonuclease H (RN

237 antiviral analogues also potently inhibited reverse transcriptase (RT) associated RNase H, implying

238 Reverse transcriptase (RT) derived base substitution mut

239 This protein contains endonuclease (EN) and reverse transcriptase (RT) domains that are necessary fo

240 Most reverse transcriptase (RT) enzymes belong to a single pr

241 RNA aptamers that bind HIV-1 reverse transcriptase (RT) inhibit HIV-1 replication, bu

242 he clinical benefits of HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are hinde

243 Nucleoside reverse transcriptase (RT) inhibitors (NRTIs) are the ba

244 Some mutations result because reverse transcriptase (RT) lacks 3' to 5' proofreading e

245 silent K65K and K66K mutations in the HIV-1 reverse transcriptase (RT) occur in over 35% of drug-exp

246 Reverse transcriptase (RT) of human immunodeficiency vir

247 Retroviral reverse transcriptase (RT) of Moloney murine leukemia vi

248 Formation of the mature HIV-1 reverse transcriptase (RT) p66/p51 heterodimer requires

249 HIV-1 reverse transcriptase (RT) possesses both DNA polymerase

250 Deep sequencing of HIV reverse transcriptase (RT) was performed (Roche/454), an

251 tified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase,

252 HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variabili

253 Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RN

254 rived vector containing an RNase H-deficient reverse transcriptase (RT).

255 CRISPR systems, Cas1 is naturally fused to a reverse transcriptase (RT).

256 -phenotype datasets of HIV protease (PR) and reverse transcriptase (RT).

257 antiretroviral (HAART) therapy targeting HIV reverse transcriptase (RT).

258 geting the essential viral polymerase, HIV-1 reverse transcriptase (RT).

259 immunodeficiency virus (SIV) carrying HIV-1 reverse transcriptase (RT-SHIV), compared to uninfected

260 arily driven by an increase in nonnucleoside reverse-transcriptase (RT) inhibitor (NNRTI) resistance

261 Bacterial group II intron reverse transcriptases (RTs) function in both intron mob

262 Protease and reverse transcriptase sequences from 876 new HIV diagnos

263 e analyzed non-B HIV-1 gag and pol (protease/reverse-transcriptase) sequences from Cameroonians for d

264 ervations using thermostable group II intron reverse transcriptase sequencing (TGIRT-seq) to characte

265 annotations of branch site are imprecise as reverse transcriptase skips several nucleotides while tr

266 ) profiling method that couples rG4-mediated reverse transcriptase stalling with next-generation sequ

267 racterize the gene coding for the telomerase reverse transcriptase subunit PpTERT in P. patens, for w

268 The reverse transcriptase telomerase adds telomeric repeats

269 occurring mutations in the ribonucleoprotein reverse transcriptase, telomerase, are associated with t

270 scripts previously classified as products of reverse transcriptase template switching are both enrich

271 eats to chromosomal ends and consists of the reverse transcriptase TERT and the RNA subunit TERC.

272 c repeats using an active site in telomerase reverse transcriptase (TERT) and an integral RNA subunit

273 minimally comprises the catalytic telomerase reverse transcriptase (TERT) and telomerase RNA (TR) tha

274 inear chromosomes, using a unique telomerase reverse transcriptase (TERT) and template in the telomer

275 d in 10 telomere-related genes including the reverse transcriptase (TERT) and the RNA component (TERC

276 Reactivation of telomerase reverse transcriptase (TERT) expression is found in more

277 l lymphoma DNA confirmed that the telomerase reverse transcriptase (TERT) gene promoter is a common A

278 mline deletion in intron 3 of the telomerase reverse transcriptase (TERT) gene that predisposes to CH

279 Differential regulation of telomerase reverse transcriptase (TERT) genes contribute to distinc

280 uisition of promoter mutations in telomerase reverse transcriptase (TERT) in blood leukocytes of appr

281 single-nucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate deh

282 Transcriptional reactivation of telomerase reverse transcriptase (TERT) reconstitutes telomerase ac

283 Additionally, SVs were confirmed in telomere reverse transcriptase (TERT) upstream regions in several

284 ic repeats, the catalytic subunit telomerase reverse transcriptase (TERT) uses the RNA subunit (TER)

285 genesis-associated genes IGF2 and telomerase reverse transcriptase (TERT) were overexpressed in fibro

286 of mutations in the promoter for telomerase reverse transcriptase (TERT), along with BRAF alteration

287 of telomere length-1 (RTEL1) and telomerase reverse transcriptase (TERT), genes involved in telomere

288 ably, with only binding sites for telomerase reverse transcriptase (TERT), minimized hTR assembled bi

289 g dysregulated growth may express telomerase reverse transcriptase (TERT), the dual function of which

290 mong 6,835 cancers, 73% expressed telomerase reverse transcriptase (TERT), which was associated with

291 integral telomerase RNA (TER) and telomerase reverse transcriptase (TERT).

292 ing activity of thermostable group II intron reverse transcriptases (TGIRTs) for DNA-seq library cons

293 n RNA-protein complex that includes a unique reverse transcriptase that catalyzes the addition of sin

294 verall stability or expression of telomerase reverse transcriptase, these rare genetic disorders are

295 ach leverages the DNA polymerase activity of reverse transcriptase to simultaneously perform proximit

296 etecting in vivo chemical modifications uses reverse transcriptase truncation products, which introdu

297 the full length of protease and part of the reverse transcriptase was packaged into a modified lenti

298 hermore, recombinant AREG induced telomerase reverse transcriptase, which appeared to be essential fo

299 t suppresses viral replication by inhibiting reverse transcriptase, which may restore the HBV-specifi

300 HTBS recruits HIV reverse transcriptase, which nucleates DNA synthesis and